Acurx Pharmaceuticals LLC
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potenti… Read more
Acurx Pharmaceuticals LLC (ACXP) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.001x
Based on the latest financial reports, Acurx Pharmaceuticals LLC (ACXP) has a cash flow conversion efficiency ratio of -0.001x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.88 Million) by net assets ($3.64 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Acurx Pharmaceuticals LLC - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Acurx Pharmaceuticals LLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Acurx Pharmaceuticals LLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Acurx Pharmaceuticals LLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Wise Group AB
ST:WISE
|
0.075x |
|
Tisdale Clean Energy Corp.
OTCQB:TCEFF
|
-0.026x |
|
Norben Tea & Exports Limited
NSE:NORBTEAEXP
|
-0.061x |
|
AECI Ltd
JSE:AFE
|
0.035x |
|
Minco Silver Corporation
OTCQX:MISVF
|
-0.007x |
|
Capital Engineering Network Public Company Limited
BK:CEN
|
0.024x |
|
General Environmental Conservation Public Company Limited
BK:GENCO
|
0.006x |
|
Blue Energy Ltd
AU:BLU
|
-0.009x |
Annual Cash Flow Conversion Efficiency for Acurx Pharmaceuticals LLC (2019–2024)
The table below shows the annual cash flow conversion efficiency of Acurx Pharmaceuticals LLC from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $615.12K | $-10.38 Million | -16.880x | -703.75% |
| 2023-12-31 | $4.67 Million | $-9.80 Million | -2.100x | -103.69% |
| 2022-12-31 | $7.32 Million | $-7.54 Million | -1.031x | -155.22% |
| 2021-12-31 | $12.41 Million | $-5.01 Million | -0.404x | +67.44% |
| 2020-12-31 | $2.70 Million | $-3.35 Million | -1.241x | +74.48% |
| 2019-12-31 | $819.85K | $-3.99 Million | -4.861x | -- |